Developer docs
API playgroundTry for free, no card

Search company profiles

George Clinical

Full company profile

uuid02m15f1

Namestring
George Clinical
Legal namestring
Emerald Clinical Trials
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered, full-service global contract research organization that has operated for more than 25 years. The company runs Phase I–IV and real-world clinical studies for pharmaceutical and biotechnology sponsors, organized around three flagship therapeutic areas — renal (its world-leading specialty with 100+ studies across 70+ countries), oncology (106,000+ participants enrolled across 2,200+ sites), and cardiovascular — together with adjacent cardiometabolic and early-phase work. Service modules span Early Phase Studies, Clinical Trial Management (study design and start-up, patient recruitment, project management, risk-based monitoring, endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. Core technology is a clinical trial management platform supporting Phase I–IV and real-world studies, with risk-based monitoring and automation in pharmacovigilance cited as proprietary feature areas.

The business model is professional services delivered on a project-based, quote-priced, multi-year contract basis to enterprise pharmaceutical buyers and biotech sponsors; pricing is not publicly disclosed and is set by scope, therapeutic complexity, phase, and geography. Go-to-market is consultative enterprise field sales — direct engagement via 'Request a proposal' CTAs — augmented by scientific thought leadership (KOL spotlights, webinars, content marketing), industry-conference presence (SOHO, BioJapan, ERA, ASCO, Obesity Science & Innovation, Precision in Clinical Trials Summit), and social channels including LinkedIn, X, Facebook, and WeChat. Emerald claims relationships with 15 of the world's top 20 pharmaceutical firms and 160+ biotech companies, delivered through in-country teams across Singapore, Australia, New Zealand, the Philippines, India, Malaysia, South Korea, China, the UK, the US, and broader EMEA. The company rebranded from George Clinical to Emerald Clinical Trials and underwent a CEO transition in July 2025 when Glenn Kerkhof was appointed interim CEO.

Short descriptiontext

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered full-service global CRO that runs Phase I–IV and real-world trials for pharma and biotech sponsors, with world-leading renal expertise alongside oncology and cardiovascular capabilities.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, clinical trial management, pharmacovigilance services, renal clinical research, oncology clinical trials
Industry2 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Full-service CRO providing end-to-end clinical trial solutions including trial management, regulatory consulting, safety services, medical writing, and data management. Revenue is generated through project-based service contracts with biotech and pharmaceutical sponsors across all phases of clinical development.

emeraldclinical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Other
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based pricing determined by scope of work, therapeutic area complexity, trial phase, and geographic reach. Quote-based engagement model typical for CRO services.

emeraldclinical.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Emerald Clinical Trials (formerly George Clinical) is a full-service global contract research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies) for biotech and pharmaceutical sponsors. Core therapeutic franchises are Renal, Oncology, and Cardiovascular, supplemented by service modules including Early Phase Studies, Clinical Trial Management, Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Consistently high recruitment and retention rates
+2 more records
Product overview1 text field

Emerald Clinical Trials (formerly George Clinical) is a full-service global clinical research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies). The company's platform centers on three core therapeutic areas—Renal (their flagship expertise with 100+ studies across 70+ countries), Oncology (with 2,200+ sites and 106,000+ participants enrolled), and Cardiovascular—supplemented by comprehensive service modules including Early Phase Studies, Clinical Trial Management (with sub-services for study design, patient recruitment, project management, monitoring, and endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. The offering combines scientific leadership with operational excellence from an Asia-Pacific base, extending services globally through teams in China, EMEA, and the Americas.

Product and service11 records
1Early Phase Studies
CategoryClinical Trial Services
Description

Phase I clinical trial services providing foundational safety and dosing data for drug development programs, anchored by Australian early-phase capabilities.

2Clinical Trial Management
CategoryClinical Trial Services
Description

End-to-end trial management encompassing study design and start-up, patient recruitment, project management, risk-based clinical trial monitoring, and endpoint adjudication across global trial sites.

3Safety & Pharmacovigilance Services
CategoryClinical Trial Services
Description

Comprehensive safety surveillance with seamless monitoring throughout the product lifecycle, backed by 20+ years of experience and advanced automation for flexible global compliance solutions.

4Regulatory Consulting
CategoryRegulatory Services
Description

Regulatory strategy and consulting services tailoring approaches to client needs, streamlining clinical trial execution from start-up through safety reporting.

5Medical Writing
CategoryClinical Trial Services
Description

Professional medical writing services supporting clinical documentation throughout the drug development lifecycle.

6Data Management & Biostatistics
CategoryClinical Trial Services
Description

Comprehensive clinical data management and biostatistics services ensuring data quality, integrity, and regulatory compliance.

7Renal Research
CategoryTherapeutic Area Services
Description

World-leading renal research expertise with over 100 renal studies conducted across 70+ countries, guided by the world's foremost renal experts with proven operational excellence and high recruitment rates.

8Oncology Research
CategoryTherapeutic Area Services
Description

Global oncology trial expertise with over 106,000 participants enrolled across 2,200+ sites worldwide, spanning Australian Early Phase to global Phase III trials with oncology-specialized teams.

9Cardiovascular Research
CategoryTherapeutic Area Services
Description

Cardiovascular trial services with comprehensive end-to-end capabilities, guided by multidisciplinary clinician and researcher KOLs and informed by deep regional insights across global populations.

10Accelerated Oncology Proof-of-Concept
CategorySpecialized Therapeutic Service
Description

Specialized oncology service designed to accelerate proof-of-concept milestones through adaptive trial design and rapid execution strategies.

11Real-World Studies
CategoryClinical Trial Services
Description

Real-world evidence studies complementing traditional clinical trial data with post-market surveillance and observational research capabilities.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Key Opinion Leaders (KOLs) and Investigators Network
Strategic tierCoreTypeOthers
Description

Emerald Clinical partners with top investigators and KOL networks globally to drive faster, smarter development in renal, oncology, cardiometabolic, and early-phase research. These relationships enable access to leading clinical researchers and facilitate study design and execution.

emeraldclinical.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Privately held global full-service CRO and commercialization provider across clinical development and post-approval services. Competes across Phase I-IV with both pharma and biotech sponsors.

TypeBroad incumbent
Description

Top-3 global CRO post-PRA Health acquisition, offering full-service clinical development with strong biotech and pharma sponsor rosters. Competes for Phase II–IV and biotech CRO work globally.

TypeBroad incumbent
Description

World's largest CRO with end-to-end Phase I-IV capabilities, deep technology/data platforms, and global infrastructure across all major therapeutic areas. Competes with Emerald for enterprise pharma RFPs and mega-deals.

TypeBroad incumbent
Description

Privately held global full-service CRO (owned by EQT/Goldman Sachs) competing for Phase I-IV trials and biotech/pharma enterprise sponsors. Comparable in offering breadth and therapeutic expertise.

TypeDirect peer
Description

Mid-sized, US-headquartered full-service CRO specializing in small-to-mid biotech sponsors with therapeutic-area depth in oncology, cardiovascular, and metabolic disease. Most directly comparable peer in business model and sponsor segment.

TypeDirect peer
Description

Privately held mid-sized full-service CRO with strong therapeutic expertise and a global footprint focused on biotech and mid-sized pharma. Comparable in scale, therapeutic depth, and operational model.

TypeDirect peer
Description

Mid-sized, scientifically-led global CRO focused on complex therapeutic areas including oncology and cardiometabolic disease, serving mid-sized pharma and biotech. Closely comparable in scale, model, and therapeutic positioning.

TypeRegional player
Description

China's largest domestic CRO providing full-service clinical trial services across all phases. Regional peer competing primarily in China and APAC biotech sponsor segments that overlap with Emerald's footprint.

TypeDirect peer
Description

Asia-Pacific-headquartered, mid-sized full-service CRO focused on biotech clinical trials across multiple therapeutic areas. Direct competitor for APAC-anchored biotech sponsors and overlapping therapeutic expertise in oncology.

TypeBroad incumbent
Description

Major global clinical trials and diagnostics provider through Covance, with broad Phase I-IV capabilities and deep pharma/biotech relationships. Competes for full-service enterprise CRO contracts.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

George Clinical

Contract Research Servicesgeorgeclinical.com

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered full-service global CRO that runs Phase I–IV and real-world trials for pharma and biotech sponsors, with world-leading renal expertise alongside oncology and cardiovascular capabilities.

What George Clinical does

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered, full-service global contract research organization that has operated for more than 25 years. The company runs Phase I–IV and real-world clinical studies for pharmaceutical and biotechnology sponsors, organized around three flagship therapeutic areas — renal (its world-leading specialty with 100+ studies across 70+ countries), oncology (106,000+ participants enrolled across 2,200+ sites), and cardiovascular — together with adjacent cardiometabolic and early-phase work. Service modules span Early Phase Studies, Clinical Trial Management (study design and start-up, patient recruitment, project management, risk-based monitoring, endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. Core technology is a clinical trial management platform supporting Phase I–IV and real-world studies, with risk-based monitoring and automation in pharmacovigilance cited as proprietary feature areas.

The business model is professional services delivered on a project-based, quote-priced, multi-year contract basis to enterprise pharmaceutical buyers and biotech sponsors; pricing is not publicly disclosed and is set by scope, therapeutic complexity, phase, and geography. Go-to-market is consultative enterprise field sales — direct engagement via 'Request a proposal' CTAs — augmented by scientific thought leadership (KOL spotlights, webinars, content marketing), industry-conference presence (SOHO, BioJapan, ERA, ASCO, Obesity Science & Innovation, Precision in Clinical Trials Summit), and social channels including LinkedIn, X, Facebook, and WeChat. Emerald claims relationships with 15 of the world's top 20 pharmaceutical firms and 160+ biotech companies, delivered through in-country teams across Singapore, Australia, New Zealand, the Philippines, India, Malaysia, South Korea, China, the UK, the US, and broader EMEA. The company rebranded from George Clinical to Emerald Clinical Trials and underwent a CEO transition in July 2025 when Glenn Kerkhof was appointed interim CEO.

George Clinical firmographics

Firmographics
Name
George Clinical
Legal name
Emerald Clinical Trials
Website
https://georgeclinical.com
Company type
Private
Operating status
Operating
Short description
Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered full-service global CRO that runs Phase I–IV and real-world trials for pharma and biotech sponsors, with world-leading renal expertise alongside oncology and cardiovascular capabilities.
Ownership category
akta.pro rank

George Clinical industry classification

Industry
Product category
Contract Research Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Contract research organization
  • Clinical trial management
  • Pharmacovigilance services
  • Renal clinical research
  • Oncology clinical trials

Where George Clinical is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices12 records

Markets served

George Clinical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: Full-service CRO providing end-to-end clinical trial solutions including trial management, regulatory consulting, safety services, medical writing, and data management. Revenue is generated through project-based service contracts with biotech and pharmaceutical sponsors across all phases of clinical development.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing determined by scope of work, therapeutic area complexity, trial phase, and geographic reach. Quote-based engagement model typical for CRO services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

George Clinical product offering

Product offering

Core offering

Emerald Clinical Trials (formerly George Clinical) is a full-service global contract research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies) for biotech and pharmaceutical sponsors. Core therapeutic franchises are Renal, Oncology, and Cardiovascular, supplemented by service modules including Early Phase Studies, Clinical Trial Management, Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics.

Product overview

Emerald Clinical Trials (formerly George Clinical) is a full-service global clinical research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies). The company's platform centers on three core therapeutic areas—Renal (their flagship expertise with 100+ studies across 70+ countries), Oncology (with 2,200+ sites and 106,000+ participants enrolled), and Cardiovascular—supplemented by comprehensive service modules including Early Phase Studies, Clinical Trial Management (with sub-services for study design, patient recruitment, project management, monitoring, and endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. The offering combines scientific leadership with operational excellence from an Asia-Pacific base, extending services globally through teams in China, EMEA, and the Americas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early Phase Studies Phase I clinical trial services providing foundational safety and dosing data for drug development programs, anchored by Australian early-phase capabilities.
  • Clinical Trial Management End-to-end trial management encompassing study design and start-up, patient recruitment, project management, risk-based clinical trial monitoring, and endpoint adjudication across global trial sites.
  • Safety & Pharmacovigilance Services Comprehensive safety surveillance with seamless monitoring throughout the product lifecycle, backed by 20+ years of experience and advanced automation for flexible global compliance solutions.
  • Regulatory Consulting Regulatory strategy and consulting services tailoring approaches to client needs, streamlining clinical trial execution from start-up through safety reporting.
  • Medical Writing Professional medical writing services supporting clinical documentation throughout the drug development lifecycle.
  • Data Management & Biostatistics Comprehensive clinical data management and biostatistics services ensuring data quality, integrity, and regulatory compliance.
  • Renal Research World-leading renal research expertise with over 100 renal studies conducted across 70+ countries, guided by the world's foremost renal experts with proven operational excellence and high recruitment rates.
  • Oncology Research Global oncology trial expertise with over 106,000 participants enrolled across 2,200+ sites worldwide, spanning Australian Early Phase to global Phase III trials with oncology-specialized teams.
  • Cardiovascular Research Cardiovascular trial services with comprehensive end-to-end capabilities, guided by multidisciplinary clinician and researcher KOLs and informed by deep regional insights across global populations.
  • Accelerated Oncology Proof-of-Concept Specialized oncology service designed to accelerate proof-of-concept milestones through adaptive trial design and rapid execution strategies.
  • Real-World Studies Real-world evidence studies complementing traditional clinical trial data with post-market surveillance and observational research capabilities.

Quantifiable outcome

  • Consistently high recruitment and retention rates
  • +2 more outcomes

Companies that use George Clinical

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

George Clinical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

George Clinical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Key Opinion Leaders (KOLs) and Investigators NetworkcoreOthersEmerald Clinical partners with top investigators and KOL networks globally to drive faster, smarter development in renal, oncology, cardiometabolic, and early-phase research. These relationships enable access to leading clinical researchers and facilitate study design and execution.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

George Clinical competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Privately held global full-service CRO and commercialization provider across clinical development and post-approval services. Competes across Phase I-IV with both pharma and biotech sponsors.
  • ICON plc: Top-3 global CRO post-PRA Health acquisition, offering full-service clinical development with strong biotech and pharma sponsor rosters. Competes for Phase II–IV and biotech CRO work globally.
  • IQVIA: World's largest CRO with end-to-end Phase I-IV capabilities, deep technology/data platforms, and global infrastructure across all major therapeutic areas. Competes with Emerald for enterprise pharma RFPs and mega-deals.
  • Parexel International: Privately held global full-service CRO (owned by EQT/Goldman Sachs) competing for Phase I-IV trials and biotech/pharma enterprise sponsors. Comparable in offering breadth and therapeutic expertise.
  • Labcorp (Covance Clinical Trials): Major global clinical trials and diagnostics provider through Covance, with broad Phase I-IV capabilities and deep pharma/biotech relationships. Competes for full-service enterprise CRO contracts.

Direct peers

  • Medpace: Mid-sized, US-headquartered full-service CRO specializing in small-to-mid biotech sponsors with therapeutic-area depth in oncology, cardiovascular, and metabolic disease. Most directly comparable peer in business model and sponsor segment.
  • PSI CRO: Privately held mid-sized full-service CRO with strong therapeutic expertise and a global footprint focused on biotech and mid-sized pharma. Comparable in scale, therapeutic depth, and operational model.
  • Worldwide Clinical Trials: Mid-sized, scientifically-led global CRO focused on complex therapeutic areas including oncology and cardiometabolic disease, serving mid-sized pharma and biotech. Closely comparable in scale, model, and therapeutic positioning.
  • Novotech: Asia-Pacific-headquartered, mid-sized full-service CRO focused on biotech clinical trials across multiple therapeutic areas. Direct competitor for APAC-anchored biotech sponsors and overlapping therapeutic expertise in oncology.

Regional players

  • Tigermed (Hangzhou Tigermed): China's largest domestic CRO providing full-service clinical trial services across all phases. Regional peer competing primarily in China and APAC biotech sponsor segments that overlap with Emerald's footprint.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

George Clinical social profiles

Digital presence

George Clinical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

George Clinical leadership team

Management profile

Number of profiles

Profiles2 records

George Clinical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

George Clinical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about George Clinical

What does George Clinical do?

Emerald Clinical Trials (formerly George Clinical) is a full-service global contract research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies) for biotech and pharmaceutical sponsors. Core therapeutic franchises are Renal, Oncology, and Cardiovascular, supplemented by service modules including Early Phase Studies, Clinical Trial Management, Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics.

Is George Clinical a public or private company?

George Clinical is a private company. It is classified as unknown and is currently operating.

When was George Clinical founded?

George Clinical was founded in -1.

Where is George Clinical based?

George Clinical is headquartered in Singapore, Singapore, in the Asia region.

How does George Clinical make money?

One revenue line is on record: clinical Research Services.

Who are George Clinical's main competitors?

Broad incumbents on record are Syneos Health, ICON plc, IQVIA, Parexel International and Labcorp (Covance Clinical Trials). Direct peers are Medpace, PSI CRO, Worldwide Clinical Trials and Novotech. Tigermed (Hangzhou Tigermed) is listed as a regional player.

Does George Clinical have an API?

No public API is recorded for George Clinical.

What industry is George Clinical in?

George Clinical's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEmerald Clinical Trials bestätigt Übergangs- und Kontinuitätsplan für CEOEmerald Clinical Trials announced the resignation of CEO Mary Gunn with immediate effect, appointing board member and CRO veteran Glenn Kerkhof as interim CEO. The company, a leading global contract research organization headquartered in Singapore, has initiated a formal search for a permanent successor. Kerkhof brings over 30 years of industry experience, including prior leadership roles at Chiltern and as Executive Chairman of George Clinical (now Emerald Clinical Trials).PR NewswireGeorge Clinical Welcomes Tony Proctor as Chief Financial OfficerGeorge Clinical appointed Tony Proctor as Chief Financial Officer, bringing over 25 years of financial leadership experience. He previously served as CFO at Lexitas, Parexel, and Syneos Health, and holds a CPA license. The company expects his expertise to support its global growth.GlobeNewswireZyVersa Therapeutics Engages CRO, George Clinical, forZyVersa Therapeutics selected George Clinical to manage its Phase 2a trial of Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease patients. The trial is expected to begin in the first quarter of 2024. The company plans to use results to guide development for other renal indications.YahooZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200ZyVersa Therapeutics selected George Clinical to manage its Phase 2a clinical trial of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease. The trial is expected to begin in the first quarter of 2024, and it is the first clinical trial for VAR 200.GlobeNewswireGeorge Clinical Selected as CRO for Hummingbird Bioscience’s Phase 1 Oncology Trials in AustraliaGeorge Clinical announced it is preparing for two Phase 1b oncology trials in Australia for Hummingbird Bioscience's anti-HER3 drug HMBD-001, targeting biomarker-selected patients including lung cancer. The trials will evaluate safety, tolerability, and dose, with the company providing full-service CRO expertise.PR NewswireGeorge Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific regionFrost & Sullivan awarded George Clinical the 2023 Asia-Pacific Competitive Strategy Leadership Award for its execution in the contract research organization industry. The recognition highlights George Clinical's ability to combine academic research connections with global operational processes to deliver tailored, high-quality clinical trial services. This strategic approach has established the company as a preferred partner in the APAC sector, particularly in kidney, oncology, and neurology research.ContractpharmaGeorge Clinical to Support Hummingbird’s Phase 1 Oncology TrialsGeorge Clinical will provide full-service clinical research for Hummingbird Bioscience's Phase 1b oncology trials in Australia. The trials test HMBD-001, an anti-HER3 antibody, in biomarker-selected patients, including lung cancer. The company aims to bring the precision therapy to Australian cancer patients.Australian Financial ReviewPE investor Hillhouse hits sensitive data snag at George Clinical, re-cut on cardsHillhouse Capital, an Asia-based investment shop, will restructure its deal to acquire Australian clinical trials business George Clinical. The restructuring aims to get the acquisition past the Foreign Investment Review Board.GlobeNewswireGeorge Clinical to Accelerate International Growth Through Acquisition by HillhouseGeorge Clinical entered a sale agreement with Hillhouse, a global investment firm, to accelerate its international growth. The acquisition provides new investment and backing for expansion in Asia-Pacific clinical research services. The transaction is subject to FIRB approval.GlobeNewswireGeorge Clinical to Accelerate International Growth Through Acquisition by HillhouseGeorge Clinical entered a sale agreement with Hillhouse, a global investment firm, to accelerate its international growth. The deal provides new investment and backing for expansion in Asia-Pacific clinical research services. The transaction is subject to FIRB approval.